Eli Lilly (NYSE:LLY) is rapidly establishing itself as the leader in GLP-1 treatments for weight loss. Its Zepbound injection has driven strong sales, contributing to the company’s overall revenue ...
Investor's Business Daily on MSN
Why FedEx stock is falling despite earnings surprise and price target hikes
The company remains in cost-cutting mode. On Thursday, FedEx said that its operating results improved in the second quarter, ...
Eli Lilly stock hits a 90+ Quality score. BofA calls LLY underpriced, citing major growth ahead for its oral obesity drug.
Investor's Business Daily on MSN
Nike beats Q2 views, but these factors drag shares lower
Nike CEO Elliott Hill said the Dow Jones giant is in the "middle innings of our comeback" after topping Q2 estimates.
The pharmaceutical leader has established itself as the leader in the fast-growing weight loss market. And although many ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback